Holen Sie sich die Stockscreener-App
8.99
5.64%
0.48
Handel nachbörslich:
8.99
Schlusskurs vom Vortag:
$8.51
Offen:
$8.45
24-Stunden-Volumen:
247.02K
Relative Volume:
0.71
Marktkapitalisierung:
$294.86M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-7.0787
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+0.11%
1M Leistung:
-14.22%
6M Leistung:
-34.67%
1J Leistung:
+24.52%
1-Tages-Spanne:
$8.25
$9.055
1-Wochen-Bereich:
$8.25
$9.09
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
8.99 | 279.12M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases - The Manila Times
Medicare Maintains Critical Coverage: NeuroPace Epilepsy Treatment Reimbursement Secured for 2025 - Stock Titan
Essex Investment Management Co. LLC Acquires Shares of 138,426 NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
What makes NeuroPace Inc. stock price move sharplyFree Stock Trend Scanner For 2025 - jammulinksnews.com
Is NeuroPace Inc. a growth stock or a value stockEntry Signal Planner To Watch Now - jammulinksnews.com
Published on: 2025-07-30 18:03:00 - metal.it
NeuroPace Inc. Earnings Report Breakdown: What Investors Should KnowPattern Alert With ROI Driven Strategy Shared - metal.it
Why NeuroPace Inc. stock attracts strong analyst attentionFast Return Equity Trade Forecast Points to Small Caps - beatles.ru
Legato Capital Management LLC Purchases Shares of 41,107 NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 - 富途牛牛
Medical Device Maker NeuroPace Sets Q2 Earnings Date: Key Updates Expected for Epilepsy Treatment Leader - Stock Titan
How Efficient Is NeuroPace Inc. at Controlling Operating CostsReal Trader Watchlist of Hot Stocks Released - metal.it
What risks could impact NeuroPace Inc. stock performanceEarnings Play Trade Plan With Alerts Shared - metal.it
Should I hold or sell NeuroPace Inc. stock in 2025Market Forecast Alerts Backed By Experts - jammulinksnews.com
What markets is NeuroPace Inc. expanding into Is JKHY stock a good long term investment optionBeginner Investor Planner For Fast Growth - jammulinksnews.com
What institutional investors are buying NeuroPace Inc. stockInvest confidently with real-time market updates - jammulinksnews.com
When is NeuroPace Inc. stock expected to show significant growthAchieve rapid capital gains with smart investing - jammulinksnews.com
Is it the right time to buy NeuroPace Inc. stockBuild a portfolio that outperforms the market - jammulinksnews.com
Does NeuroPace Inc. stock perform well during market downturnsBuild wealth steadily with expert advice - jammulinksnews.com
How does NeuroPace Inc. compare to its industry peersHigh-performance stocks for savvy investors - jammulinksnews.com
How does NeuroPace Inc. generate profit in a changing economyBreakneck growth rates - jammulinksnews.com
Is NeuroPace Inc. stock overvalued or undervaluedRapid wealth multiplication - jammulinksnews.com
How volatile is NeuroPace Inc. stock compared to the marketHigh-impact investment strategies - jammulinksnews.com
What is the dividend policy of NeuroPace Inc. stockGame-changing capital returns - jammulinksnews.com
NeuroPace Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Access to Investment Community - beatles.ru
What are NeuroPace Inc. company’s key revenue driversDiscover breakthrough trading strategies - jammulinksnews.com
What are the latest earnings results for NeuroPace Inc.Unlock powerful insights from market experts - jammulinksnews.com
How NeuroPace Inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
Does NeuroPace Inc. stock pay reliable dividendsFree Signals Group - Newser
NeuroPace Inc. Stock Analysis and ForecastOutstanding risk-reward balance - PrintWeekIndia
Is NeuroPace Inc. a good long term investmentTremendous growth opportunities - Autocar Professional
What analysts say about NeuroPace Inc. stockExceptional financial outcomes - PrintWeekIndia
What drives NeuroPace Inc. stock priceFree Trading Strategy Suggestions - PrintWeekIndia
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.21%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):